Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio is currently developing a promising pipeline of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, the most advanced of which is their main product candidate, prulacabtagene leucel (prula-cel). The preliminary Phase 1 data released last year showed strong efficacy and safety in both lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients, with 100% of LN patients achieving a renal response and significant reductions in SLE symptoms. With promising data, a less toxic profile, and potential for multiple indications in the future, Adicet Bio's stock has the potential to see significant upside.

Bears say

Adicet Bio is facing potential delays and regulatory challenges with its product candidates, as evidenced by the pushed back release date of topline results for prula-cel and the need for further interactions with the FDA for its LN pivotal study. While the company has a strong cash position, its ongoing need for financing puts it at risk for dilution and drag on earnings. This, coupled with potential competition in the market, leads to a negative outlook for Adicet Bio's stock.

ACET has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACET has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.